-+ 0.00%
-+ 0.00%
-+ 0.00%

Oncoinvent's Ovarian Cancer Drug Radspherin Shows Favorable Safety Profile

MT Newswires·11/17/2026 02:04:01
Listen to the news
02:04 AM EST, 11/17/2026 (MT Newswires) -- Oncoinvent's (ONCIN.OL) investigational ovarian cancer drug Radspherin showed a favorable safety profile in an interim safety analysis of its ongoing phase 2 trial. The drug was evaluated in patients with peritoneal metastases from advanced ovarian cancer, the biotechnology company said Tuesday. There were no serious adverse events considered related to Radspherin in the randomized trial. The trial's independent data monitoring committee recommended that the trial continue without modification. Recruitment in the phase 2 trial is expected to complete in the first half of 2027, with the interim efficacy readout expected in April 2027.